Loading...
XSHG600664
Market cap1.32bUSD
Dec 26, Last price  
3.83CNY
1D
-1.03%
1Q
12.32%
Jan 2017
-55.36%
Name

Harbin Pharmaceutical Group Co.

Chart & Performance

D1W1MN
XSHG:600664 chart
P/E
24.40
P/S
0.62
EPS
0.16
Div Yield, %
0.00%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
7.41%
Revenues
15.46b
+11.93%
7,174,900,4908,493,388,6329,197,583,7618,290,269,9019,695,068,09210,677,300,58012,535,439,81213,486,960,37417,662,946,86318,091,934,50216,508,912,52515,856,207,77814,126,885,95412,017,531,25110,813,613,59411,824,561,67510,788,456,54812,802,015,55313,808,761,32715,456,578,104
Net income
395m
-15.02%
262,960,783456,151,984461,606,327591,806,581862,319,976932,928,6401,130,244,886578,658,929499,645,016168,668,871247,105,656580,132,712788,103,136406,975,865346,139,970121,868,3040371,083,746465,150,300395,263,436
CFO
950m
+52.66%
149,006,562757,762,170738,083,489650,162,694578,587,2631,851,593,0101,152,668,5480557,829,737141,639,6971,136,099,5881,660,015,4002,778,011,578149,221,463692,724,935000622,093,201949,670,974
Dividend
May 04, 20180.5 CNY/sh

Profile

Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trade of pharmaceuticals in China and internationally. The company operates through seven segments: Antibiotics, Small-Molecular Drug Preparations, OTC and Healthcare Products, Modern Chinese Medicines, Biopharmaceuticals, Animal Vaccines, and Medicine Circulations. It offers a series of penicillin and cephalosporin products, as well as intermediates. The company's lead products include Shuang Huanglian freeze-dried injection; Danshen freeze-dried injection; Shuang Huanglian powder for injection; roxithromycin dispersible tablets; belladonna, sulfamethoxazole, and trimerhoprim tablets; pediatric paracetamol, atificial cow-bezoar, and chlorphenamine maleate granules; Shuanghuanglian oral liquid; and ceftriaxone sodium for injection. Its lead products also comprise amoxicillin capsules, cefotiam hydrochloride for injection, panax ginseng extract, cefepime hydrochloride for injection, cefoperazone sodium for injection, and amoxicillin sodium and clavulanate potassium for injection; cefuroxime sodium, ceftazidime, cefotaxime sodium, and ceftriaxone sodium for injections; and ampicillin capsules. In addition, the company offers medical protective and disposable surgical masks, medical disposable protective gowns, and isolation gowns. It offers its products under the Hongyan Yaopin, Guangwei, Renmin Tongtai, Hayao Shengwu, Baohulu, Manshanhong, Hutong, Hayaoliu, Gaizhonggai, Sanchine, Shiyitang, and Hayao brands. The company is based in Harbin, China.
URL
https://www.hayao.com/
IPO date
Jun 29, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
15,456,578
11.93%
13,808,761
7.86%
12,802,016
18.66%
Cost of revenue
13,525,017
12,413,014
11,340,422
Unusual Expense (Income)
NOPBT
1,931,561
1,395,747
1,461,593
NOPBT Margin
12.50%
10.11%
11.42%
Operating Taxes
176,322
190,065
220,689
Tax Rate
9.13%
13.62%
15.10%
NOPAT
1,755,239
1,205,683
1,240,904
Net income
395,263
-15.02%
465,150
25.35%
371,084
 
Dividends
Dividend yield
Proceeds from repurchase of equity
(4,635)
16,979
15,533
BB yield
0.06%
-0.22%
-0.17%
Debt
Debt current
1,793,338
2,080,197
2,217,354
Long-term debt
94,783
120,552
157,300
Deferred revenue
319,073
333,611
375,104
Other long-term liabilities
375,708
69,704
94,703
Net debt
(1,210,705)
(318,235)
678,120
Cash flow
Cash from operating activities
949,671
622,093
CAPEX
(86,535)
Cash from investing activities
72,336
91,615
Cash from financing activities
147,942
174,617
393,265
FCF
2,166,878
1,698,212
1,026,911
Balance
Cash
3,060,402
2,433,495
1,592,106
Long term investments
38,424
85,488
104,428
Excess cash
2,325,997
1,828,546
1,056,433
Stockholders' equity
5,146,718
4,750,531
4,231,941
Invested Capital
5,329,595
5,470,868
6,002,747
ROIC
32.50%
21.02%
21.22%
ROCE
25.21%
19.11%
20.70%
EV
Common stock shares outstanding
2,470,396
2,579,776
2,506,955
Price
3.35
11.30%
3.01
-15.21%
3.55
11.29%
Market cap
8,275,828
6.58%
7,765,126
-12.75%
8,899,691
11.29%
EV
7,763,873
8,141,433
10,220,000
EBITDA
2,235,961
1,706,142
1,769,138
EV/EBITDA
3.47
4.77
5.78
Interest
69,445
85,535
105,155
Interest/NOPBT
3.60%
6.13%
7.19%